Sign in
Enrolling by invitationNo phase

International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.

Key facts

Who runs it
Hospital Universitario La Paz
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
100 people, planned
Started
1 Aug 2025
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Sentinel Lymph Node Biopsy in first local recurrent vulvar carcinoma
Record updated
17 June 2025

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • First local recurrent squamous cell carcinoma of the vulva (SCC)
  • Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus
  • No distant or groin metastasis
  • To be able to understand the study and sign informed consent
  • Over 18 years old
  • To be able to undergo planned follow up

Who cannot take part

  • Previous bilateral IFL
  • Multifocal recurrent disease of the vulva
  • Synchronous, non-curable second malignancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Acronym: VULCA-NODE Study Title: Sentinel Node Biopsy in Relapsed Vulvar Cancer Primary Objetive: To evaluate the SLN detection rate in the first recurrent vulvar carcinoma setting.

Read full original descriptionShow less

Secondary Objetives:

* To compare the utility of different tracers in the detection of SLN for recurrent disease and the injection pattern. * To evaluate the surgical complications rate. * To analyze the nodal status by ultrastaging . * To assess the disease free and overall survival at 24 months from the first recurrence, as well as the dissemination pattern after the procedure.

Study Design: International prospective multicentre study

Inclusion Criteria:

* First local recurrent squamous cell carcinoma of the vulva (SCC). * Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus. * No distant or groin metastasis. * To be able to understand the study and sign informed consent. * Over 18 years old. * To be able to undergo planned follow up.

Exclusion Criteria:

* Multifocal recurrent disease of the vulva. * Previous bilateral IFL. * Synchronous, non-curable second malignancy. Timing: 4 years

The group in the trial

  • First local recurrent vulvar carcinomaTreatment being tested

    Treatment: Sentinel Lymph Node Biopsy in first local recurrent vulvar carcinoma

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sentinel Node Biopsy in Relapsed Vulvar Cancer. VULCA-NODE Study.
Record updated
17 June 2025